Urate-Lowering Therapy Explained

Quick take

The useful answer first.

01The usual NICE target is below 360 µmol/L (6 mg/dL), with a lower target considered in some circumstances.

02Early flares can occur while crystal deposits are changing.

03Long-term adherence matters because symptom-free periods do not necessarily mean the crystal burden has disappeared.

The context

What sits behind the quick answer.

The goal is crystal reduction over time

Urate-lowering therapy aims to keep serum urate below a target so existing crystal deposits can reduce and new crystal formation becomes less likely. This is a different job from treating the pain and inflammation of an acute flare.

Why flares can still happen early

Flares can occur during the early months of urate lowering as crystal deposits change. That does not automatically mean the long-term strategy has failed.

Targets provide feedback

NICE recommends a treat-to-target strategy. The usual target is below 360 µmol/L (6 mg/dL), with a lower target considered in some people with more severe gout.

In real life

How to use this without overthinking it.

1Know your target and how it is being monitored.

2Keep a simple record of urate results and flares.

3Discuss dose changes, side effects and flare prevention with the clinician managing treatment.

Evidence & safety

Keep the boundaries clear.

GoutSense separates general evidence from individual medical advice. Food and lifestyle context can be useful, but it does not diagnose gout and should not be used to start, stop or alter prescribed medication.

Evidence review: September 2026Editorial standard: practical answer → evidence → limitations